The Burden of Mucosal Barrier Injury Laboratory-confirmed Bloodstream Infection Among Hematology, Oncology and Stem Cell Transplant Patients

In 2013, Centers for Disease Control and Prevention released a revised central line-associated bloodstream infection (CLABSI) surveillance protocol which differentiates laboratory-confirmed bloodstream infection (LCBI) from mucosal barrier injury LCBI (MBI-LCBI). The objectives of this study were to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of infection control 2014-06, Vol.42 (6), p.S12-S13
Hauptverfasser:	Metzger, Kristen, MPH, CIC, Rucker, Yvonne, MSN, RN, NE-BC, OCN, Callaghan, Mary, MN, RN, AOCNS, APN, Churchill, Michelle, MSN, ANP-BC, OCN, Bolon, Maureen, MD, MS
Format:	Artikel
Sprache:	eng
Schlagworte:	Blood Infection Control Infections Infectious Disease Stem cells Transplants & implants
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In 2013, Centers for Disease Control and Prevention released a revised central line-associated bloodstream infection (CLABSI) surveillance protocol which differentiates laboratory-confirmed bloodstream infection (LCBI) from mucosal barrier injury LCBI (MBI-LCBI). The objectives of this study were to determine the proportion of CLABSIs classified as MBI-LCBI among hematology/oncology (Heme/Onc) and stem cell transplant patients (SCT), compare characteristics of non-MBI LCBI and MBI-LCBI cases, and evaluate how CLABSI prevention efforts affect non-MBI LCBI and MBI-LCBI rates.
ISSN:	0196-6553 1527-3296
DOI:	10.1016/j.ajic.2014.03.049